Online Supplementary Table S8

Table S8. Summary of key safety results up to week 24 in the full analysis set.

	GP2013 N = 133 n (%)	RTX N = 179 N (%)
Serious AEs (SAEs)	9 (6.8)	18 (10.1)
Any AEs	80 (60.2)	100 (55.9)
- Leading to study drug discontinuation	4 (3.0)	9 (5.0)
- Suspected by the investigator to be related	40 (30.1)	50 (27.9)
AEs by most frequent SOCs		
- Infections and infestations	34 (25.6)	46 (25.7)
- Musculoskeletal	19 (14.3)	23 (12.8)
- Gastrointestinal disorders	15 (11.3)	26 (14.5)
- General disorders	18 (13.5)	15 (8.4)
- Skin and subcutaneous tissue	14 (10.5)	17 (9.5)
- Injury and poisoning	13 (9.8)	16 (8.9)
- Respiratory, thoracic disorders	11 (8.3)	19 (10.6)
- Vascular disorders	12 (9.0)	13 (7.3)
- Nervous system disorders	10 (7.5)	19 (10.6)
Infusion related reaction* on day or day after 1st infusion	21 (15.8)	27 (15.1)
Infusion related reaction* on day or day after the 2nd infusion	10 (7.5)	9 (5.0)

* Adverse events potentially related to the infusion were collected using a Novartis MedDRA Query (NMQ – 90000721).